K4 Elite logo K4 Elite
Home / Peptide Library / CJC-1295
Emerging Research

CJC-1295

Hormonal & Endocrine · ['DAC:GRF', 'CJC-1295 with DAC', 'Modified GRF (1-29) analog']

A long-acting growth-hormone-releasing hormone analog studied for extended stimulation of GH secretion via serum-albumin binding.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C165H269N47O46
Molecular Weight
3647.2 g/mol
PubChem
CID 91971820 ↗
Research Level
Emerging Research
Browse the store →
CJC-1295 chemical structure

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) engineered with amino-acid substitutions and, in its drug-affinity-complex (DAC) form, a maleimido group that binds covalently to circulating serum albumin. This design was intended to greatly extend the peptide's half-life relative to native GHRH or sermorelin.

Research has examined it as a tool for producing sustained elevation of growth hormone and IGF-1 through the same pituitary pathway used by endogenous GHRH, while resisting rapid enzymatic degradation.

The extended-action property has made it a subject of pharmacokinetic and endocrine research on the GH/IGF-1 axis.

CJC-1295 activates the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, stimulating cyclic-AMP-mediated synthesis and release of growth hormone. Substitutions at positions susceptible to enzymatic cleavage increase metabolic stability.

In the DAC form, covalent binding to serum albumin markedly prolongs circulating half-life, which studies report sustains elevated GH and IGF-1 levels over an extended window compared with shorter-acting GHRH analogs.

  • Pharmacokinetic studies of albumin-binding drug-affinity-complex technology for extended half-life [1]
  • Investigation of sustained GH and IGF-1 elevation via the GHRH receptor [1]
  • Comparative endocrine studies against sermorelin and native GHRH [2]
  • Study of pulsatile versus tonic GH secretion patterns in the GH axis [2]
  • Exploration of combined secretagogue signaling with ghrelin-receptor agonists [2]
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Half-life and GH response (human) [1]: A clinical pharmacokinetic study administered CJC-1295 and measured serum drug concentration, GH, and IGF-1 over time, reporting a prolonged elevation of IGF-1 consistent with the extended half-life produced by albumin binding.

Dose-ranging endocrine assessment (human) [1]: Escalating-dose research measured mean GH and IGF-1 changes and safety endpoints, characterizing the duration and magnitude of GH-axis stimulation across doses.

Comparative GHRH-analog studies (preclinical) [2]: Animal and cell studies compared receptor activation and stability of modified GHRH analogs against native peptide, measuring GH output and degradation resistance.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

IpamorelinSynergistic
Ghrelin-receptor agonist studied in combination where GH release was reported additive in models.
GHRP-2 / GHRP-6Synergistic
Secretagogues investigated together with GHRH analogs for combined GH stimulation.
SomatostatinCaution
Endogenous inhibitor of GH release opposing GHRH-analog action in study conditions.
Serum albuminCompatible
The DAC form binds albumin by design to extend circulating half-life.
  1. Teichman et al., CJC-1295 pharmacokinetics and GH/IGF-1 (J Clin Endocrinol Metab)
  2. Alba et al., Long-acting GHRH analog in GH-deficient models (Endocrinology / review)
  3. PubChem CID 91971820 (CJC-1295)
What is CJC-1295?
It is a long-acting analog of growth-hormone-releasing hormone studied for sustained stimulation of the pituitary GH axis.
Why does it last longer than sermorelin?
Stabilizing substitutions plus, in the DAC form, covalent binding to serum albumin extend its circulating half-life in reported pharmacokinetic studies.
What receptor does it target?
The growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells.
What has research examined?
Studies have focused on pharmacokinetics of albumin-binding technology and sustained GH and IGF-1 elevation through the native GHRH pathway.
Is this available for personal use?
No. This entry is for research use only and is not intended for human or veterinary use, diagnosis, or treatment.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.